|
| 
 |
|
 |
|
|
|
 |
NEWS |
 |
|
|
 |
Daiichi initiates phase III trial of thromboembolism drug
 |
|
| Daiichi Sankyo has initiated a large-scale pivotal phase III trial for edoxaban, its investigational oral factor Xa inhibitor. This new study is evaluating the safety and efficacy of edoxaban in reducing venous thromboembolic complications |
|
|
|
|
|
Korean firm completes hypertension drug trial
|
|
| Boryung Pharmaceutical, one of South Korea's largest pharmaceutical companies, has completed its final clinical test on a new drug that will help treat patients with high blood pressure |
|
|
|
|
|
|
 |
|
 |
|
|
|
|
|
|
|
|
|
|
FEATURES |
|
|
|
|
Bionomics of Biosimilars
|
|
| Biosimilars are said to be the next big cash cow for India. However, players have many knots to untangle before they can have a firm grip over the economics of the market |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PEOPLE |
|
|
|
|
GSK Japan gets new President
|
|
| GlaxoSmithKline has appointed Mr Philippe Fauchet as the President of GSK Japan. Mr Fauchet joins GSK from Sanofi Aventis where he was Senior Vice President, Business Development |
|
|
|
|
|
China Biologic appoints independent director
|
|
| China Biologic Products, a leading plasma-based biopharmaceutical company in China, announced that, effective February 4, 2010, the company has appointed Dr. Xiangmin Cui, to serve as an independent member of its board of directors, as the Chairman |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PRODUCTS |
|
|
|
|
Waters introduces Acquity UPLC H-Class System
|
|
| According to the company, the new H-Class system is designed to replace High Performance Liquid Chromatography (HPLC) systems and accelerate Ultra Performance Liquid Chromatography (UPLC) adoption among HPLC users |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
